Examples of Consulting Services Provided

  • Large Biopharma, Cambridge, MA 2019 to date. Advising on novel approach to launch a proprietary gene therapy product into an ophthalmic rare disease market
  • Advising Top Tier Venture Capital Firm on Alzheimer’s Disease Company, 2019 to date. Providing the President with an assessment of the clinical data, the next stage in the clinical development and commercial considerations to support a Series B financing
  • Radiopharmaceutical oncology company, 2019 to date. Providing CEO and board strategic advice and supporting its series A financing and potential spin-off of its diagnostics business.
  • European Gene Therapy company, 2019 to 2020. Advising company on readying itself to enter the US market for financing and the clinical development of its lead siRNA product in the cancer space.
  • Large Biopharma, Cambridge, MA 2018 to 2019. Advising on novel approach to launch a proprietary monoclonal antibody product into a major new neuroscience $3.6 billion market
  • Oncology EU biotech firm, 2019 to 2020. Advising clinical stage EU company developing a novel therapeutic oncology biologic, in partnering program, negotiating collaborations and supporting its financing efforts
  • POC and digital diagnostic company, Boston, 2018 to date Providing strategic and e-commerce partnership advice in the $9 billion STI diagnostic market
  • Health IT company, Boston, 2018 to date Advising health IT company on strategy, business development and customer acquisition in the $150 billion appointment optimization business for US health systems
  • European Cell Therapy Company, Acting CEO, 2017 to 2019 Providing leadership on financing, strategy, product development, and business development for a cell therapy approach in oncology. Have secured meetings with top blue-chip VCs and multiple big pharma companies, obtained 8 million Euro grant in Janssen/NUIG consortium.
  • CRISPR Gene Therapy Company, Cambridge, MA, 2018. Advised gene therapy company on IP issues: negotiated and signed multiple in-licensing deals for key technologies to allow them to develop products with freedom to operate
  • Kidney Replacement Company, Los Angeles, CA, 2018 to 2019. Advised a medical device company in the kidney disease space to create a development plan and budget, and make introductions to form strategic partnerships for commercializing its products
  • Gene Therapy company Boston, MA, 2016 to 2018. Provide strategic, product development, financing and business development support in the gene therapy space. Closed first financing in October 2017, and $50 million series A in September 2018.
  • Blood Product Company Investor, Boston, MA, 2016 to 2018. Provide strategic, business development, financing, manufacturing development and regulatory support. Oversee build out of a new pharmaceutical facility.
  • Health IT & Provider company, Phoenix, Arizona, 2013 to date. Provide advice on strategy, business operations, supported multiple financings, clinical study design and analysis, in the health IT space and the treatment of chronic care patients with multiple conditions
  • Cell Therapy Company, Cambridge, MA, 2017. Provided operational and strategic manufacturing build out analysis and proposal to commercialize the cell therapy approach
  • Investment Fund, Lexington, KY 2017 Provided market and product assessment for a potential generic pharmaceutical company investment. Advised on market trends, fit and competitive analysis.
  • MAb Device Delivery Company., Chief Operating Officer, 2013 to 2017, and advisor to date. Provided an MIT technology drug delivery company product development and strategic alliance guidance, raised over $36 million, including strategic investors Sanofi and 3M, completed first clinical studies, and drove a major business development initiative culminating in their first $100M+ deal with Takeda.
  • Small molecule pain company President, CEO, Executive Chairman, Board, Boston, 2012 to 2015. Advising on product development, partnering opportunities and financing for biotech delta opioid receptor agonist product. Closed co-development deal with a Pharma company.
  • Rapid POC diagnostic company, Boston, 2012 to 2015 Consulting on strategy, operations, manufacturing and commercial launch planning of a POC diagnostic for CD4 and Viral Load counts to help combat AIDS & HCV in key African states with rapid expansion to other developing country regions and eventually the EU and USA.
  • New generation gene sequencing Diagnostic company., Lexington, Acting Chief Operating Officer 2012 to 2014. A start up genomic diagnostic company developing a test for the early detection of Autism. Provided strategic and commercial planning support, recalibrated operations, and execution support of QSR, a pivotal clinical study, and commercial go to market plan. Providing on-going strategic advice.
  • Advised large Biotech Company, Lexington, 2012 to 2014 on new product/company acquisitions using a Company/Venture Capital Firm model to reduce risk, costs and accelerate POC data.
  • Created practical business plans, investment rationales and launch plans for biotechnology companies in the areas of neurology, metabolic disease and cancer.
  • Devised a biotechnology company business strategy, product development plan and financing proposal; gained a $10M financing offer from a top tier VC.
  • Advised new start-ups, in the areas of new drugs, cell therapies and devices, services and retail.
  • Coached executives on strategic planning, business plans, marketing and operations.

Consulting Options

Testimonials